TABLE 1.

Clinical trials of mesenchymal stromal cells (MSCs) in acute respiratory distress syndrome (ARDS) (completed)

Clinical trial ID	study	Name of clinical trial	Phase	MSC type	Dose	Frequency	Route	Patients Enrolled	Follow up
NCT01902082	Zheng et al.9	Adipose-derived mesenchymal stem cells in acute respiratory distress syndrome	Phase 1	AD-MSCs	1 × 106/kg	once	i.v.	20(10/10)	28 days
NCT01775774	Wilson et al.10	Human mesenchymal stromal cells for acute respiratory distress syndrome (START)	Phase 1	BM-MSC	1,5,10 × 106/kg	once	i.v.	9(3/3/3)	12 months
NCT02097641	Matthay et al.11	START	Phase2a	BM-MSC	1 × 107/kg	once	i.v.	60(40/20)	12 months
NCT02611609	Bellinga et al.12	A phase 1/2 study to assess multistem therapy in acute respiratory distress syndrome (MUST-ARDS)	Phase 1/2	MultiStem	300/900million	once	i.v.	30(10/10/10)	12 months
NCT02095444	Chen et al.77	Using human menstrual blood cells to treat acute lung injury caused by H7N9 bird flu virus infection	Phase 1/2	MB-MSC	1∼10 × 107 cells/kg	4 times	i.v.	20	5 years